- Home
- BH vs LENZ Comparison
BH vs LENZ Comparison
Compare BH & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- LENZ
- Stock Information
- Founded
- BH 1934
- LENZ 2019
- Country
- BH United States
- LENZ United States
- Employees
- BH N/A
- LENZ N/A
- Industry
- BH Restaurants
- LENZ Medicinal Chemicals and Botanical Products
- Sector
- BH Consumer Discretionary
- LENZ Health Care
- Exchange
- BH Nasdaq
- LENZ Nasdaq
- Market Cap
- BH 677.5M
- LENZ 679.4M
- IPO Year
- BH N/A
- LENZ 2021
- Fundamental
- Price
- BH $212.01
- LENZ $24.75
- Analyst Decision
- BH
- LENZ Strong Buy
- Analyst Count
- BH 0
- LENZ 6
- Target Price
- BH N/A
- LENZ $35.40
- AVG Volume (30 Days)
- BH 4.7K
- LENZ 150.7K
- Earning Date
- BH 03-21-2025
- LENZ 03-19-2025
- Dividend Yield
- BH N/A
- LENZ 58.15%
- EPS Growth
- BH N/A
- LENZ N/A
- EPS
- BH N/A
- LENZ N/A
- Revenue
- BH $362,114,000.00
- LENZ N/A
- Revenue This Year
- BH N/A
- LENZ N/A
- Revenue Next Year
- BH N/A
- LENZ N/A
- P/E Ratio
- BH N/A
- LENZ N/A
- Revenue Growth
- BH N/A
- LENZ N/A
- 52 Week Low
- BH $159.69
- LENZ $2.57
- 52 Week High
- BH $271.35
- LENZ $38.93
- Technical
- Relative Strength Index (RSI)
- BH 36.04
- LENZ 55.66
- Support Level
- BH $207.69
- LENZ $21.98
- Resistance Level
- BH $221.66
- LENZ $23.92
- Average True Range (ATR)
- BH 9.30
- LENZ 1.42
- MACD
- BH -2.83
- LENZ 0.37
- Stochastic Oscillator
- BH 10.69
- LENZ 84.27
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations, and Maxim. The majority of revenue is derived from the Restaurant Operations segment. The Restaurant Operations segment includes Steak n Shake and Western Sizzlin Restaurant businesses.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.